American Regent begins enrolment in Phase III trial of Injectafer to treat heart failure

Japanese pharmaceutical firm Daiichi Sankyo's division, American Regent, has begun patient enrolment in the Phase III HEART-FID clinical trial of Injectafer (ferric carboxymaltose) for the treatment of heart failure with iron deficiency.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news